ASH 2023 | Managing adverse risk AML: clinical considerations & future outlooks
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, briefly discusses the management of adverse risk acute myeloid leukemia (AML), including TP53-mutated and complex karyotype AML subtypes. Dr Fathi highlights the need to transition away from traditional intensive chemotherapy to less cytotoxic therapeutic agents, for example hypomethylating agents (HMAs), which are better tolerated by patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy and advisory activities: Amgen, Servier, Takeda, Orum, Daiichi Sankyo, Menarini, Rigel, Remix, Abbvie, Astellas, BMS, Ipsen, Gilead, Pfizer, Genentech, AstraZeneca, Autolus, Syndax
Clinical trial funding: Abbvie, Servier, BMS
